Loading
Diabetes Treatment and Management / Neurological Disorders and Treatments / Pancreatic Function and Diabetes · Journal article
International Journal of Innovative Technologies in Social Science · August 31, 2026
Raises a question worth testing. It does not answer one.
This is a narrative literature review that examines the potential neuroprotective properties of SGLT2 inhibitors in Alzheimer and Parkinson disease based on receptor distribution in the central nervous system and recent published evidence. The source describes the review methodology and scope but does not report specific findings, effect sizes, or conclusions about clinical efficacy; it presents the question rather than answering it with evidence.
Qualitative literature review. Published literature on SGLT2 inhibitors and neurodegenerative disorders; source does not specify settings or enrolment of study participants. Intervention: SGLT2 inhibitors (flozins/gliflozins) examined for neuroprotective properties in central nervous system.
SGLT2 receptors are present in the central nervous system, suggesting possible neuroprotective properties with SGLT2i use in Alzheimer and Parkinson disease Literature search covered publications primarily from the past 10 years, conducted November 2023 to May 2026, using PubMed database with MeSH terms
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review does not provide sufficient evidence to guide clinical practice regarding SGLT2 inhibitor use in neurodegenerative disease. Clinicians should await the review's substantive findings and primary clinical trial data before considering off-label use.
A qualitative literature review summarizing mechanistic evidence and observational studies on SGLT2 inhibitors in neurodegenerative disease; raises questions about neuroprotective potential but reports no primary clinical trial data or effect sizes to support practice change.
As stated by the source record.
This review does not provide sufficient evidence to guide clinical practice regarding SGLT2 inhibitor use in neurodegenerative disease. Clinicians should await the review's substantive findings and primary clinical trial data before considering off-label use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
SGLT2i (sodium-glucose cotransporter 2 inhibitors), also called flozins or gliflozins, are a group of hypoglycemic agents that have revolutionized the approach in treatment of T2DM (type 2 diabetes mellitus). Recent years have witnessed a rise in number of neurological conditions, which requires novel approaches to be examined to provide neuroprotection in these patients. Some studies suggest that presence of SGLT2 receptors in the central nervous system can provide possible neuroprotective properties in Alzheimer and Parkinson disease with the use of SGLT2i. We aimed in this review to summarize current evidence of SGLT2i impact on the central nervous system (CNS), as well to define their potential role in the comprehensive management of patients with neurologic disorders. Methods and materials: A qualitative synthesis of the data focusing on SGLT2 inhibitors, Alzheimer and Parkinson disease was performed. This literature review of SGLT2 inhibitors effect on neuroprotection in neurodegenerative disorders included recent publications, primarily from the past 10 years, and was conducted from November 2023 to May 2026 using the PubMed database. We performed a systematic search using specific keywords and medical subject headings (MeSH terms) related to SGLT2 inhibitors, Alzheimer and Parkinson disease. The primary search terms were: “SGLT2 inhibitors”, “sodium-glucose cotransporter 2 inhibitors”, “Alzheimer disease”, “Parkinson disease”, “neuroprotection”, “mild cognitive impairment”, and “flozins”. The criteria for inclusion of articles were as follows: published before May 2026, written in English, peer-reviewed original research articles. Exclusion criteria included publications not available in full text, articles in languages other than English. Editorials, commentaries, and conference abstracts without full data were also excluded. Titles and abstracts of the retrieved articles were screened to determine eligibility based on the inclusion and exclusion criteria.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.